NCT00493129View on ClinicalTrials.gov

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
LeukemiaSystemic Mastocytosis
Interventions
DRUG

Ontak (Denileukin Diftitox)

9 µg/kg by vein Days 1-5 of a 21 day cycle.

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00493129 - Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | Biotech Hunter | Biotech Hunter